rare side effects of semaglutide 7 Risks A potentially blinding condition is

Each pen is for single patient use only

The difference becomes more pronounced with higher-dose injectable semaglutide: Wegovy (2.4 mg weekly) demonstrated mean weight loss of approximately 15% of body weight in the STEP clinical trial program for obesity management, substantially exceeding outcomes typically seen with oral semaglutide at diabetes-approved doses

Roger L, Tomas F, Gire V

In the analyses we compared the use of GLP-1 RAs and use of SGLT-2 inhibitors or DPP-4 inhibitors, respectively

2 As with most of the beneficial effects of GLP-1 in type-2 diabetic patients, the exact mechanism by which it induces satiety is not known and more research is underway